Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MesoPher plus mitazalimab in metastatic pancreatic cancer after FOLFIRINOX
NL-OMON52234Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Aug 2021
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of MesoPher and mitazalimab in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC), sponsored by Erasmus MC. Primary endpoint: Dose-limiting toxicities. Started Aug 2021; status: active, not recruiting.
02
Drugs
MesoPhermitazalimab
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON52234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52234.